Oklahoma Health Care Authority
Drug Utilization Review Board
(DUR Board)
Meeting – October 10, 2012 @ 6:00 p.m.

Oklahoma Health Care Authority
2401 N.W. 23rd Street, Suite 1-A
Oklahoma City, Oklahoma 73107
Ponca Room (North Entrance)

AGENDA
Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:

1. Call To Order
- A. Roll Call – Dr. Cothran

Items to be presented by Dr. Muchmore, Chairman:

2. Public Comment Forum
- A. Acknowledgment of Speakers and Agenda Items

Items to be presented by Dr. Muchmore, Chairman:

3. Action Item – Approval of DUR Board Meeting Minutes – See Appendix A.
- A. September 12, 2012 DUR Minutes – Vote
- B. September 13, 2012 DUR Recommendation Memorandum

Items to be presented by Dr. Keast, Dr. Muchmore, Chairman:

4. Update on DUR / Medication Coverage Authorization Unit – See Appendix B.
- A. Retrospective Drug Utilization Review Response for April 2012
- B. Medication Coverage Activity for September 2012
- C. Pharmacy Help Desk Activity for September 2012
- D. Retrospective Drug Evaluation: Focusing on Safety

Items to be presented by Dr. Weber, Dr. Muchmore, Chairman

5. Action Item – Vote to Prior Authorize Cialis® – See Appendix C.
- A. COP Recommendations

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman

6. Action Item – Vote to Prior Authorize Neupro® – See Appendix D.
- A. COP Recommendations

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman

7. **Action Item – Annual Review of Bladder Control Medications and 30 Day Notice to Prior Authorize Myrbetriq™ – See Appendix E.**
   A. Current Authorization Criteria
   B. Utilization Review
   C. Prior Authorization Review
   D. Market News and Update
   E. COP Recommendations
   F. Utilization Details
   G. Myrbetriq™ Product Details

Items to be presented by Dr. Le, Dr. Muchmore, Chairman

8. **Action Item – Annual Review of Antidepressants and 30 Day Notice to Prior Authorize Forfivo XL™ and Fluoxetine 60mg – See Appendix F.**
   A. Current Authorization Criteria
   B. Utilization Review
   C. Prior Authorization Review
   D. Market News and Update
   E. COP Recommendations
   F. Utilization Details
   G. Forfivo XL™ Product Details

Items to be presented by Dr. Sipols, Dr. Le, Dr. Muchmore, Chairman

9. **Action Item – Annual Review of Alzheimer's Medications® – See Appendix G.**
   A. Current Authorization Criteria
   B. Utilization Review
   C. Prior Authorization Review
   D. Market News and Updates
   E. COP Recommendations
   F. Utilization Details

Items to be presented by Dr. Moore, Dr. Muchmore, Chairman

10. **30 Day notice to Prior Authorize Miscellaneous Butalbital Products – See Appendix H.**
    A. Overview
    B. Cost Comparison
    C. COP Recommendations
    D. Product Information

Items to be presented by Dr. Cothran, Dr. Muchmore, Chairman

11. **FDA and DEA Updates – See Appendix I.**

12. **Future Business**
    A. Annual Reviews
    B. New Product Reviews
    C. Utilization Review of COPD Medications

13. **Adjournment**